President and CEO of the Central Indiana Corporate Partnership
Professor of Systems Biology, Columbia University
Managing Director of Hatteras Discovery and Venture Partner at Hatteras Venture Partners
Founder and Managing Partner, Frazier Healthcare Ventures
Is conventional equity funding for innovation in the life sciences industry truly a viable strategy for private equity and venture capital firms, or is it all just a house of cards? Against a backdrop that includes some local criticism of Big Pharma’s hardball buyout tactics, the San Diego Venture Group has organized a debate on the merits of the venture-backed biotech business model. Making the case for venture biotech innovation are Wende Hutton of Canaan Partners and Camille Samuels of Versant Ventures; Arguing for a change are Bob More of Frazier Healthcare and Kevin Kinsella of Avalon Ventures. More information and online registration is available here.